Gene info: ID 2249

Gene: FGF4

GENE ID: 2249

Description: fibroblast growth factor 4

Gene type: protein-coding

Location: 11q13.3

dbXrefs: Ensembl:ENSG00000075388 MIM:164980 Vega:OTTHUMG00000167887 UniprotKB:P08620

RefSeq: NC_000011.10

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 2

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 9.084e-1 (AD) 4.433e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR5M8	0.744
OR4Q2	0.631
OR8H1	0.624
MAGEB10	0.623
OR10W1	0.619
MYF5	0.616
CRISP1	0.612
KRTAP12-3	0.608
DEFB121	0.606
OR2W5	0.606

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
YIPF7	-0.265
ZNF404	-0.219
MLYCD	-0.195
ENPP5	-0.19
DNASE1L2	-0.19
B3GALT1	-0.189
TMEM56	-0.187
TMEM116	-0.186
ZNF177	-0.185
GTPBP8	-0.185

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00686	Pentosan Polysulfate	Small Molecule	37300-21-3	Approved	Target
DB01109	Heparin	Small Molecule	9005-49-6	Approved\|Investigational	Target
DB05309	TP-508	Small Molecule	-	Investigational	Target

ID	Drug Name	Action	PubMed
C511295	2,2',4,4'-tetrabromodiphenyl ether	"2,2',4,4'-tetrabromodiphenyl ether results in increased expression of FGF4 mRNA"	25614096
C026137	3-hydroxyacetanilide	3-hydroxyacetanilide results in decreased expression of FGF4 mRNA	18544908
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in decreased expression of FGF4 mRNA	18544908
D019342	Acetic Acid	Acetic Acid results in increased expression of FGF4 protein	21296659
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of FGF4 mRNA	16483693
C015001	arsenite	arsenite results in decreased methylation of FGF4 promoter	23974009
C487081	belinostat	belinostat results in increased expression of FGF4 mRNA	26272509
C487081	belinostat	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA"	27188386
D004958	Estradiol	Estradiol results in increased expression of FGF4 mRNA	21098263
C006780	bisphenol A	bisphenol A results in decreased expression of FGF4 mRNA	25270620
C006780	bisphenol A	bisphenol A results in decreased expression of FGF4 mRNA	25181051
C000611646	bisphenol F	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FGF4 mRNA	28628672
C099813	bromochloroacetic acid	bromochloroacetic acid results in increased expression of FGF4 protein	21296659
D002104	Cadmium	Cadmium results in increased expression of FGF4 mRNA	24376830
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of FGF4	17707671
D002220	Carbamazepine	Carbamazepine affects the expression of FGF4 mRNA	25979313
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of FGF4 gene	20938992
D003300	Copper	Copper deficiency results in increased expression of FGF4 mRNA	26033743
C014347	decitabine	decitabine results in increased expression of FGF4 mRNA	27915011
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FGF4 mRNA	28628672
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate affects the expression of FGF4 mRNA	26924002
D019422	Dietary Sucrose	Dietary Sucrose results in increased expression of FGF4 mRNA	26033743
C024629	dimethyl phthalate	dimethyl phthalate affects the expression of FGF4 mRNA	26924002
D004221	Disulfiram	Disulfiram results in decreased expression of FGF4 mRNA	8805369
C118739	entinostat	entinostat results in increased expression of FGF4 mRNA	26272509
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA"	27188386
D005472	Fluorouracil	Fluorouracil affects the expression of FGF4 protein	21296659
C061365	flusilazole	flusilazole results in increased expression of FGF4 mRNA	28263823
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of FGF4 gene	20938992
D005665	Furosemide	Furosemide results in increased expression of FGF4 mRNA	16526316
D006493	Heparin	Heparin binds to and results in increased activity of FGF4 protein	11486033
D006497	Heparitin Sulfate	Heparitin Sulfate binds to FGF4 protein	15769253
D006497	Heparitin Sulfate	Heparitin Sulfate analog binds to FGF4 protein	14707131
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FGF4 mRNA	28628672
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FGF4 mRNA	28628672
C018086	isobutyl nitrite	isobutyl nitrite results in increased expression of FGF4 mRNA	16288974
D008694	Methamphetamine	[Methamphetamine co-treated with SCH 23390] results in increased expression of FGF4 mRNA	19564919
D008694	Methamphetamine	Methamphetamine results in increased expression of FGF4 mRNA	19564919
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of FGF4 gene	20938992
D008803	Mianserin	Mianserin results in decreased expression of FGF4 mRNA	24154490
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of FGF4 mRNA	26924002
C568376	MT19c compound	MT19c compound results in decreased expression of FGF4 mRNA	21781307
D010416	Pentachlorophenol	Pentachlorophenol results in increased expression of FGF4 mRNA	23892564
D011374	Progesterone	Progesterone results in decreased expression of FGF4 mRNA	21770760
C059514	resveratrol	resveratrol results in decreased expression of FGF4 mRNA	21188121
C513635	S-2-pentyl-4-pentynoic hydroxamic acid	S-2-pentyl-4-pentynoic hydroxamic acid results in decreased expression of FGF4 mRNA	21427059
C534628	SCH 23390	[Methamphetamine co-treated with SCH 23390] results in increased expression of FGF4 mRNA	19564919
C105686	SU 5402	SU 5402 results in decreased expression of FGF4 mRNA	15355794
C105686	SU 5402	SU 5402 results in decreased activity of FGF4 protein	12076337
D013605	T-2 Toxin	T-2 Toxin results in decreased expression of FGF4 mRNA	26141394
D014212	Tretinoin	Tretinoin results in increased expression of FGF4 mRNA	8805369
D014212	Tretinoin	NR6A1 protein affects the reaction [Tretinoin results in decreased expression of FGF4 mRNA]	16166633
C012589	trichostatin A	trichostatin A results in increased expression of FGF4 mRNA	24935251
D014635	Valproic Acid	Valproic Acid results in increased expression of FGF4 mRNA	24383497\|2493525
D014635	Valproic Acid	Valproic Acid results in increased methylation of FGF4 gene	29154799
D014635	Valproic Acid	Valproic Acid affects the expression of FGF4 mRNA	17292431
D014635	Valproic Acid	Valproic Acid analog results in decreased expression of FGF4 mRNA	21427059
D014635	Valproic Acid	Valproic Acid results in decreased expression of FGF4 mRNA	21427059

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004713	protein tyrosine kinase activity	-	TAS	-
GO:0005088	Ras guanyl-nucleotide exchange factor activity	-	TAS	-
GO:0005104	fibroblast growth factor receptor binding	-	IEA	-
GO:0008083	growth factor activity	-	IEA	-
GO:0008201	heparin binding	-	IEA	-
GO:0016303	1-phosphatidylinositol-3-kinase activity	-	TAS	-
GO:0046934	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000165	MAPK cascade	-	TAS	-
GO:0001502	cartilage condensation	-	IEA	-
GO:0007165	signal transduction	-	TAS	2959959
GO:0007267	cell-cell signaling	-	TAS	2959959
GO:0008284	positive regulation of cell proliferation	-	IGI	8663044
GO:0008543	fibroblast growth factor receptor signaling pathway	-	IGI	8663044
GO:0008543	fibroblast growth factor receptor signaling pathway	-	TAS	-
GO:0010463	mesenchymal cell proliferation	-	IDA	11023873
GO:0010469	regulation of signaling receptor activity	-	IEA	-
GO:0018108	peptidyl-tyrosine phosphorylation	-	IEA	-
GO:0019827	stem cell population maintenance	-	IEA	-
GO:0035116	embryonic hindlimb morphogenesis	-	IEA	-
GO:0036092	phosphatidylinositol-3-phosphate biosynthetic process	-	IEA	-
GO:0042475	odontogenesis of dentin-containing tooth	-	IEA	-
GO:0043066	negative regulation of apoptotic process	-	IEA	-
GO:0045944	positive regulation of transcription by RNA polymerase II	-	IEA	-
GO:0046854	phosphatidylinositol phosphorylation	-	IEA	-
GO:0051781	positive regulation of cell division	-	IEA	-
GO:0051897	positive regulation of protein kinase B signaling	-	TAS	-
GO:0060363	cranial suture morphogenesis	-	IEA	-
GO:0060561	apoptotic process involved in morphogenesis	-	IEA	-
GO:0060591	chondroblast differentiation	-	IDA	17167778
GO:0070374	positive regulation of ERK1 and ERK2 cascade	-	IDA	17167778
GO:1990830	cellular response to leukemia inhibitory factor	-	IEA	-
GO:2000544	regulation of endothelial cell chemotaxis to fibroblast growth factor	-	IDA	16756958

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005576	extracellular region	-	TAS	-
GO:0005622	intracellular	-	IEA	-

KEGG ID	KEGG Term
hsa04010	MAPK signaling pathway
hsa04810	Regulation of actin cytoskeleton
hsa05200	Pathways in cancer
hsa05218	Melanoma

Reactome ID	Reactome Term	Evidence
R-HSA-109704	PI3K Cascade	TAS
R-HSA-112399	IRS-mediated signalling	TAS
R-HSA-1226099	Signaling by FGFR in disease	TAS
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-1643685	Disease	TAS
R-HSA-1839122	Signaling by activated point mutants of FGFR1	TAS
R-HSA-1839124	FGFR1 mutant receptor activation	TAS
R-HSA-1839126	FGFR2 mutant receptor activation	TAS
R-HSA-1839130	Signaling by activated point mutants of FGFR3	TAS
R-HSA-190236	Signaling by FGFR	TAS
R-HSA-190239	FGFR3 ligand binding and activation	TAS
R-HSA-190241	FGFR2 ligand binding and activation	TAS
R-HSA-190242	FGFR1 ligand binding and activation	TAS
R-HSA-190322	FGFR4 ligand binding and activation	TAS
R-HSA-190372	FGFR3c ligand binding and activation	TAS
R-HSA-190373	FGFR1c ligand binding and activation	TAS
R-HSA-190375	FGFR2c ligand binding and activation	TAS
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-2033514	FGFR3 mutant receptor activation	TAS
R-HSA-2033519	Activated point mutants of FGFR2	TAS
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	TAS
R-HSA-2428924	IGF1R signaling cascade	TAS
R-HSA-2428928	IRS-related events triggered by IGF1R	TAS
R-HSA-5654219	Phospholipase C-mediated cascade: FGFR1	TAS
R-HSA-5654221	Phospholipase C-mediated cascade; FGFR2	TAS
R-HSA-5654227	Phospholipase C-mediated cascade; FGFR3	TAS
R-HSA-5654228	Phospholipase C-mediated cascade; FGFR4	TAS
R-HSA-5654687	Downstream signaling of activated FGFR1	TAS
R-HSA-5654688	SHC-mediated cascade:FGFR1	TAS
R-HSA-5654689	PI-3K cascade:FGFR1	TAS
R-HSA-5654693	FRS-mediated FGFR1 signaling	TAS
R-HSA-5654695	PI-3K cascade:FGFR2	TAS
R-HSA-5654696	Downstream signaling of activated FGFR2	TAS
R-HSA-5654699	SHC-mediated cascade:FGFR2	TAS
R-HSA-5654700	FRS-mediated FGFR2 signaling	TAS
R-HSA-5654704	SHC-mediated cascade:FGFR3	TAS
R-HSA-5654706	FRS-mediated FGFR3 signaling	TAS
R-HSA-5654708	Downstream signaling of activated FGFR3	TAS
R-HSA-5654710	PI-3K cascade:FGFR3	TAS
R-HSA-5654712	FRS-mediated FGFR4 signaling	TAS
R-HSA-5654716	Downstream signaling of activated FGFR4	TAS
R-HSA-5654719	SHC-mediated cascade:FGFR4	TAS
R-HSA-5654720	PI-3K cascade:FGFR4	TAS
R-HSA-5654726	Negative regulation of FGFR1 signaling	TAS
R-HSA-5654727	Negative regulation of FGFR2 signaling	TAS
R-HSA-5654732	Negative regulation of FGFR3 signaling	TAS
R-HSA-5654733	Negative regulation of FGFR4 signaling	TAS
R-HSA-5654736	Signaling by FGFR1	TAS
R-HSA-5654738	Signaling by FGFR2	TAS
R-HSA-5654741	Signaling by FGFR3	TAS
R-HSA-5654743	Signaling by FGFR4	TAS
R-HSA-5655253	Signaling by FGFR2 in disease	TAS
R-HSA-5655302	Signaling by FGFR1 in disease	TAS
R-HSA-5655332	Signaling by FGFR3 in disease	TAS
R-HSA-5658623	FGFRL1 modulation of FGFR1 signaling	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-74751	Insulin receptor signalling cascade	TAS
R-HSA-74752	Signaling by Insulin receptor	TAS
R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
26943773	Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. (2016 Apr 5)	Tan Q	Oncotarget
22074045	The FGF and FGFR Gene Family and Risk of Cleft Lip With or Without Cleft Palate. (2013 Jan)	Wang H	Cleft Palate Craniofac J